Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

Exclusion Criteria

• •1. AKI, defined as any of the following:
• •* Increase in serum creatinine ≥0.3 mg/dl in 48h
• •* Increase in serum creatinine ≥50% in 7d (if no value available in last 7d, use most recent value in last 3 months)
• •* Urine output ≤0.5 ml/kg/h x 6 consecutive hours (only assessed in patients with hourly monitoring via Foley catheter)
• •* Receipt of renal replacement therapy (RRT) within 7d
• •2. Advanced chronic kidney disease (eGFR \<15 ml/min/1.73m2 or end-stage kidney disease receiving RRT)
• •3. Hemoglobin \<8 g/dL (closest value in the prior 3 months)
• •4. Fever (temperature ≥38⁰C) in the last 48h
• •5. Suspected or confirmed bacteremia, endocarditis, or pyelonephritis
• •6. Pneumonia, aspiration, or bilateral pulmonary infiltrates from an infectious etiology reported on chest x-ray or CT scan in the last 7d
• •7. Positive COVID-19 test within previous 10d
• •8. Chronic iron overload (including conditions such as hemochromatosis and beta thalassemia major) or previous iron chelation therapy (including prior participation in DEFEAT-AKI)
• •9. Known hypersensitivity to deferoxamine
• •10. Taking prochlorperazine
• •11. Severe hearing loss
• •12. Pregnant or breastfeeding
• •13. Prisoner
• •14. Concurrent participation in another interventional research study in which the intervention has potential interaction with deferoxamine
• •15. Surgery to be performed under conditions of circulatory arrest
• •16. Receiving extracorporeal membrane oxygenation
• •17. Durable ventricular assist device (VAD) prior to surgery (does not include Impella device or intra-aortic balloon pump)
• •18. Any condition which, in the judgement of the investigator, might increase the risk to the patient
• •19. Conflict with other research studies